Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 1
2006 6
2007 2
2008 3
2009 2
2010 6
2011 4
2012 5
2013 8
2014 11
2015 9
2016 6
2017 10
2018 13
2019 17
2020 22
2021 16
2022 16
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, Tanaka T, Goto H, Nakano Y, Iida N, Arai K, Yamashita T, Mizukoshi E, Nakamura H, Kaneko S, Takamura T. Takeshita Y, et al. Among authors: mizukoshi e. Diabetes Care. 2022 Sep 1;45(9):2064-2075. doi: 10.2337/dc21-2049. Diabetes Care. 2022. PMID: 35894933 Free PMC article. Clinical Trial.
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). Ozaka M, et al. Among authors: mizukoshi e. Eur J Cancer. 2023 Mar;181:135-144. doi: 10.1016/j.ejca.2022.12.014. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36652891 Free article. Clinical Trial.
Telomerase-Targeted Cancer Immunotherapy.
Mizukoshi E, Kaneko S. Mizukoshi E, et al. Int J Mol Sci. 2019 Apr 12;20(8):1823. doi: 10.3390/ijms20081823. Int J Mol Sci. 2019. PMID: 31013796 Free PMC article. Review.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators. Harrison SA, et al. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB, Nasti A, Seki A, Komura T, Inui H, Kozaka T, Kitamura Y, Shiba K, Yamashita T, Yamashita T, Mizukoshi E, Kawaguchi K, Wada T, Honda M, Kaneko S, Sakai Y. Ho TTB, et al. Among authors: mizukoshi e. J Immunother Cancer. 2020 Nov;8(2):e001367. doi: 10.1136/jitc-2020-001367. J Immunother Cancer. 2020. PMID: 33188035 Free PMC article.
Immune cell therapy for hepatocellular carcinoma.
Mizukoshi E, Kaneko S. Mizukoshi E, et al. J Hematol Oncol. 2019 May 29;12(1):52. doi: 10.1186/s13045-019-0742-5. J Hematol Oncol. 2019. PMID: 31142330 Free PMC article. Review.
Cleavage of Hsp70.1 causes lysosomal cell death under stress conditions.
Yamashima T, Mochly-Rosen D, Wakatsuki S, Mizukoshi E, Seike T, Larus IM, Chen CH, Takemura M, Saito H, Ohashi A. Yamashima T, et al. Among authors: mizukoshi e. Front Mol Biosci. 2024 May 27;11:1378656. doi: 10.3389/fmolb.2024.1378656. eCollection 2024. Front Mol Biosci. 2024. PMID: 38859931 Free PMC article. Review.
Hsp70.1 carbonylation induces lysosomal cell death for lifestyle-related diseases.
Yamashima T, Seike T, Oikawa S, Kobayashi H, Kido H, Yanagi M, Yamamiya D, Li S, Boontem P, Mizukoshi E. Yamashima T, et al. Among authors: mizukoshi e. Front Mol Biosci. 2023 Feb 3;9:1063632. doi: 10.3389/fmolb.2022.1063632. eCollection 2022. Front Mol Biosci. 2023. PMID: 36819480 Free PMC article. Review.
Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.
Yamamoto M, Terashima T, Yamashita T, Seki A, Nakagawa H, Nio K, Shimakami T, Takatori H, Arai K, Mizukoshi E, Honda M, Takeuchi S, Yamashita T. Yamamoto M, et al. Among authors: mizukoshi e. Hepatol Res. 2024 Mar;54(3):315-319. doi: 10.1111/hepr.13975. Epub 2023 Oct 24. Hepatol Res. 2024. PMID: 37817425
161 results